Natural Killer Cell-Derived Vesicular miRNAs: A New Anticancer Approach?


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
01 01 2020
Historique:
received: 08 05 2019
revised: 24 09 2019
accepted: 21 10 2019
pubmed: 2 11 2019
medline: 20 6 2020
entrez: 2 11 2019
Statut: ppublish

Résumé

Natural killer (NK) cells are cytotoxic lymphocytes targeting virus-infected cells and cancer cells. Specific pro- and antikilling signals modulate the overall ability of NK cells to kill cancer cells, however, several immune-escape mechanisms can be enacted by cancer cells to avoid NK-mediated killing. Recently, increasing evidence has shown that extracellular vesicles (EV) released by NK cells carry proteins and miRNAs able to exert an antitumoral effect, even within a highly immune-suppressive tumor microenvironment. These recent findings suggest a possible use of NK-derived EVs as anticancer agents and propel the development of new strategies to enrich EVs with the most effective anticancer cargo as a promising new anticancer approach.

Identifiants

pubmed: 31672842
pii: 0008-5472.CAN-19-1450
doi: 10.1158/0008-5472.CAN-19-1450
pmc: PMC6942618
mid: NIHMS1541585
doi:

Substances chimiques

MicroRNAs 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

17-22

Subventions

Organisme : NCI NIH HHS
ID : R01 CA215753
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA219024
Pays : United States

Informations de copyright

©2019 American Association for Cancer Research.

Références

Immunogenetics. 1999 Jul;49(7-8):731-4
pubmed: 10369937
Annu Rev Genomics Hum Genet. 2006;7:277-300
pubmed: 16824023
Cell Mol Life Sci. 2018 Jan;75(2):193-208
pubmed: 28733901
Front Immunol. 2018 Apr 23;9:824
pubmed: 29740437
Cancer Res. 2012 Jun 1;72(11):2746-56
pubmed: 22593198
Front Immunol. 2014 Feb 12;5:56
pubmed: 24575100
Small GTPases. 2017 Oct 2;8(4):220-232
pubmed: 27494381
Cancers (Basel). 2018 Oct 05;10(10):null
pubmed: 30301144
Cell. 2003 Mar 7;112(5):659-72
pubmed: 12628186
Cell Death Differ. 2010 Apr;17(4):616-23
pubmed: 20075940
Immunol Res. 2004;30(1):29-34
pubmed: 15258309
Annu Rev Immunol. 2002;20:217-51
pubmed: 11861603
Cancer Res. 2007 Feb 1;67(3):976-83
pubmed: 17283129
Theranostics. 2017 Jul 7;7(10):2732-2745
pubmed: 28819459
Cell. 2008 May 16;133(4):681-92
pubmed: 18485875
Mol Immunol. 2002 May;38(14):1007-21
pubmed: 11955593
J Immunol. 2003 Sep 1;171(5):2556-62
pubmed: 12928406
Crit Rev Immunol. 2002;22(5-6):463-82
pubmed: 12803322
Cancer Metastasis Rev. 2019 Jun;38(1-2):205-222
pubmed: 30911978
Cell Death Differ. 2012 Jan;19(1):36-41
pubmed: 22075988
J Extracell Vesicles. 2019 Mar 12;8(1):1588538
pubmed: 30891164
J Biol Chem. 2009 Dec 4;284(49):34211-22
pubmed: 19801663
Eur J Immunol. 2005 Jan;35(1):261-72
pubmed: 15593300
J Exp Med. 2002 May 20;195(10):1303-16
pubmed: 12021310
Front Immunol. 2013 Mar 20;4:69
pubmed: 23518691
J Extracell Vesicles. 2017 Nov 22;6(1):1400370
pubmed: 29209467
J Natl Cancer Inst. 2015 May 13;107(7):null
pubmed: 25972604
J Extracell Vesicles. 2014 Dec 22;3:26913
pubmed: 25536934
Asian Pac J Allergy Immunol. 2014 Mar;32(1):3-15
pubmed: 24641285
Cell. 2019 Apr 4;177(2):428-445.e18
pubmed: 30951670
Cancer Immunol Res. 2017 Oct;5(10):929-938
pubmed: 28842470
Cell. 2010 Mar 5;140(5):652-65
pubmed: 20211135
Cancer Metastasis Rev. 2019 Jun;38(1-2):93-101
pubmed: 30715644
Cancer Res. 2004 Jan 1;64(1):378-85
pubmed: 14729648
Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):E2110-6
pubmed: 22753494
Biochim Biophys Acta Rev Cancer. 2019 Apr;1871(2):273-280
pubmed: 30708040
Cancer Res. 2016 Mar 15;76(6):1381-90
pubmed: 26719539
Front Neurosci. 2018 Nov 06;12:811
pubmed: 30459547
Proc Natl Acad Sci U S A. 1999 May 11;96(10):5640-4
pubmed: 10318937
Nat Rev Drug Discov. 2013 Nov;12(11):847-65
pubmed: 24172333
Cell Biosci. 2011 Dec 28;1:41
pubmed: 22204491
J Immunol. 2012 Sep 15;189(6):2833-42
pubmed: 22904309
J Mol Biol. 2003 Jan 10;325(2):355-65
pubmed: 12488100
Cancer Res. 2019 Mar 15;79(6):1151-1164
pubmed: 30541743
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Science. 2007 Dec 21;318(5858):1931-4
pubmed: 18048652
Cent Eur J Immunol. 2014;39(1):109-15
pubmed: 26155110
Cell Mol Bioeng. 2016 Dec;9(4):509-529
pubmed: 28392840
J Extracell Vesicles. 2017 Feb 28;6(1):1294368
pubmed: 28326171
J Leukoc Biol. 1999 Nov;66(5):718-22
pubmed: 10577499
J Immunol. 2006 Nov 1;177(9):5840-51
pubmed: 17056508
Cancer Res. 2019 Apr 1;79(7):1293-1294
pubmed: 30936073
Cancer J. 2008 Jan-Feb;14(1):1-6
pubmed: 18303474
Cell Death Differ. 2008 Feb;15(2):251-62
pubmed: 17975553
Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):E11721-E11730
pubmed: 30463946
Gastroenterology. 2005 Jun;128(7):1796-804
pubmed: 15940614
PLoS One. 2016 Oct 27;11(10):e0165533
pubmed: 27788241
Semin Cell Dev Biol. 2015 Apr;40:41-51
pubmed: 25721812
J Immunol. 2016 Apr 1;196(7):2923-31
pubmed: 26994304

Auteurs

Muller Fabbri (M)

University of Hawai'i Cancer Center, Cancer Biology Program, University of Hawai'i at Manoa, Honolulu, Hawaii. mfabbri@cc.hawaii.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH